Peakdale and De Novo in strategic alliance
UK company Peakdale Molecular has entered into a joint collaboration with De Novo Pharmaceuticals to exploit the companies' respective skills in chemistry synthesis and molecular design.
UK company Peakdale Molecular has entered into a joint collaboration with De Novo Pharmaceuticals to exploit the companies' respective skills in chemistry synthesis and molecular design.
They will work together to design and supply novel compounds specifically targeted towards the discovery of new molecules active at G-protein coupled receptors (GPCRs).
Peakdale has proven chemistry expertise in the design, creation and successful synthesis of novel chemotypes that have proved to be successful in pharmaceutical research, leading to patentable compounds. De Novo has proprietary expertise for the in silico de novo design of novel chemotypes against biological enzyme and receptor targets.
The first goal of the collaboration is to make available from Peakdale a range of screening compounds suitable for use in lead discovery, initially targeted at sub-familised within the GPCR super family. Further objectives are based on the application of the acquired knowledge to increase the selectibity of the approach in collaboration with a number of partner pharmaceutical companies.
'The market for screening compounds and hit discovery services has been supplied to date with iterations of the same chemotypes, often driven by cost rather than science,' said Ray Fisher, commercial director at Peakdale Molecular. 'We are delighted with the opportunity this alliance presents as De Novo will provide chemically tractable ideas for challenging biological targers that Peakdale's chemists will be able to reduce to practice for the benefit of the drug discovery industry.